Search results
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 21 hours agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 7 hours agoModerna stock is yo-yoing after the company unveiled early-stage test results for its...
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in...
WTNH-TV New Haven· 1 day agoUpon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to...
Merck to Report Earnings One Month After Major Drug Approval. What Investors Are Watching.
Barrons.com· 5 hours agoThe Winrevair approval should help cushion the blow of the expiration of the patents protecting...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 14 hours agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows ...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Benzinga via Yahoo Finance· 9 hours agoThe investigational immuno-oncology combination demonstrates an overall response rate (ORR) of...
Merck Earnings Preview: Strong quarter expectations on the back of core products' growth
Seeking Alpha· 12 hours agoMerck (NYSE:MRK) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 12 hours agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap...
...Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in...
Morningstar· 2 days agoThe VERSATILE-002 trial is evaluating Versamune® HPV (formerly PDS0101) in combination with the immune checkpoint...